Fecal calprotectin is a protein released in the stool when there is inflammation in the intestines. It helps distinguish between inflammatory bowel disease (IBD) and non-inflammatory conditions like irritable bowel syndrome (IBS).
Calprotectin is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
Calprotectin becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
Calprotectin does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
Calprotectin is a protein found in white blood cells that is released into the stool during intestinal inflammation. Measuring fecal calprotectin provides a non‑invasive way to assess whether gut symptoms—such as diarrhea, abdominal pain, or bleeding—are caused by an inflammatory condition like Crohn’s disease or ulcerative colitis, rather than a non‑inflammatory disorder like irritable bowel syndrome.
A fecal calprotectin level below the lab-dependent cut‑off (commonly <50 mg/L) is considered normal. This makes active inflammatory bowel disease less likely and often supports a diagnosis of irritable bowel syndrome or another non‑inflammatory condition. However, mildly elevated levels can sometimes occur with infections or medications.
A fecal calprotectin level above the typical cut‑off (lab‑dependent; usually >50 mg/L) points to the presence of intestinal inflammation. Levels between 50 and 150 mg/L may reflect mild inflammation, while values consistently >150–200 mg/L are more commonly associated with active inflammatory bowel disease such as Crohn’s disease or ulcerative colitis. Other causes include infections, colorectal cancer, or use of non‑steroidal anti‑inflammatory drugs.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
Calprotectin becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Fecal Calprotectin alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
Most laboratories consider a fecal calprotectin level below 50 mg/L as normal, indicating no significant intestinal inflammation. However, reference ranges can vary, so it is important to use the cut‑off provided by your testing lab.
High fecal calprotectin suggests that inflammation is present in the intestines. This is often due to inflammatory bowel disease (Crohn’s disease or ulcerative colitis), but can also be caused by infections, certain medications, or other inflammatory conditions. Very high levels typically warrant further investigation, such as colonoscopy.
In general, irritable bowel syndrome (IBS) does not cause elevated fecal calprotectin because IBS is a functional disorder without significant inflammation. Stress alone does not directly raise calprotectin levels, though it may worsen symptoms. If calprotectin is elevated, inflammatory causes should be ruled out.
Calprotectin does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
This biomarker gains value when it is connected to symptom patterns, daily function, and structured self-observation instead of being read in isolation.
Reduced capacity, multisystem symptoms, and delayed worsening often make more sense when the broader ME/CFS pattern is considered.
Markers linked to sleep, stress, recovery, hormones, or metabolism often become more useful when viewed through pacing and daily load management.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
